Novavax (NASDAQ: NVAX) Successfully Addresses FDA Clinical Hold; Trial ResumesGAITHERSBURG, Md. – Novavax, Inc. (NASDAQ: NVAX) announced on November 11, 2024, that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on Novavax’s

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Novavax’s 8K filing here.

About Novavax

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.